Heart failure

The current practice for managing heart failure is to monitor patients daily for fluid burden, either at home or in the clinic. However, the current monitoring methods are either inaccurate (weight scales) or invasive (implantable leads, implantable pulmonary artery pressure monitors).

Bioimpedance spectroscopy (BIS) offers an alternative that overcomes these limitations—noninvasively, accurately, easily and cost-effectively.

~$31 billion/year1

Heart failure related healthcare costs.

~25% of patients2

Hospital readmissions within 30 days.

12-day window

If fluid buildup is detected early, up to 12 days before readmission, readmissions can be reduced2-4

Importance of early detection

After a single heart failure hospitalization, nearly 25% of patients are readmitted within 30 days, and nearly 50% are readmitted in six months.2 However, if fluid buildup is detected early, up to 12 days before readmission, hospital readmissions can be reduced.2-4

Findings from five published papers, including three from Aachen University/Philips GmbH Innovative Technologies, show that bioimpedance spectroscopy (BIS) can detect and follow the changes in lung impedance in patients and is sensitive to extracellular volume.5 Since most patients with acute heart failure suffer not only from pulmonary edema but also from edema in the limbs, a combination of different BIS measurements offers the best option to manage the course of disease.5 Ongoing clinical studies are studying the utilization of SOZO to improve heart failure management.

SOZO®

SOZO, the world’s most advanced, noninvasive BIS device, incorporates L-Dex® technology to aid in the assessment of secondary lymphedema and delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds.

Clinical evidence

ImpediMed’s BIS technology has been extensively studied in over 40 medical conditions and disease states.

References

  1. Savarese G, Lund LH. Global public health burden of heart failure.Cardiac Failure Review. April 2017;3(1):7-11.doi:10.15420/cfr.2016:25:2.
  2. Desai AS. Home monitoring heart failure care does not improve patient outcomes: looking beyond telephone-based disease management. Circulation.2012;125(6):828-836.
  3. Yu C.M, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation.2005;112(6):841-848.
  4. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009;6(4):287-292.
  5. Weyer S, et al. Bioelectrical impedance spectroscopy as a fluid management system in heart failure. Physiol Meas.2014;35(6):917-930.